 |
 |
 |
 |
 |
 |
 |
 |
E-Mail
ShareOther Antiretrovirals in Development
See also: HIV Drugs in Development
Other Drugs
- New Drugs and Simplified Treatments Demonstrate Potential for Treating HIV (AIDS 2010) (About Kaletra, Isentress, TBR-65 and S/GSK1349572) (July 20, 2010)
In The AIDS Beacon - Gilead Sciences, Tibotec to Develop Second Once-Daily HIV Treatment (July 17, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation - High-Dose Intravenous Immunoglobulin May Reduce Latent HIV Reservoir in Resting CD4+ Cells, Study Suggests (February 10, 2009)
A five-day course of high-dose intravenous immunoglobulin appears to somehow activate replication-competent HIV in the resting CD4+ cells of patients on HAART, ultimately leading to a reduction in those patients' latent HIV reservoirs, according to the results of a nine-patient study presented by Magnus Gisslén, M.D., Ph.D.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Acyclovir: The Next New HIV Drug? (February 10, 2009)
From Project Inform - Biotechnology Company to Launch Trial of New HIV/AIDS Treatment That Would Target DNA (February 4, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Experimental Treatment Lengthens Lifespan of Monkeys With Simian Version of HIV, Study Says (December 12, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Existing Anti-Obesity Drugs May Be Effective Against Flu, Hepatitis and HIV (September 29, 2008)
From University of Rochester Medical Center - Suppression of Human Protein Reduces HIV's Ability to Enter T Cells, Replicate, Study Finds (April 30, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Not Your Everyday Antiretroviral: KP-1461, an HIV DNA Killer (October 11, 2007)
In AIDS Treatment News, from AIDS Treatment News - Peptide Found in Human Blood Inhibits 60 Strains of HIV, Study Says (April 20, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - New Vulnerability Found in AIDS Virus, German Scientists Say (August 3, 2005)
[Archived Article]
In vitro tests find that a peptide appears to halt HIV assembly.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Tat Inhibitors, a New Approach: Interview With Olaf Kutsch, Ph.D. (February 28, 2005)
[Archived Article]
Years ago, a Tat inhibitor worked well in the lab but failed in patients; modern biotechnology, however, may give the drug new life.
In AIDS Treatment News, from AIDS Treatment News - Behind the December 2004 "AIDS Breakthrough" Headlines (December 31, 2004)
[Archived Article]
Mid-December press reports were exaggerated, but still important; they focus on DAPYs, a promising new family of HIV meds.
In AIDS Treatment News, from AIDS Treatment News - Statins May Help Treat HIV (October 2004)
[Archived Article]
Quick recap of a recent study on Mevacor in the Journal of Experimental Medicine.
To read PDF, click here.
In HIV Treatment ALERTS!, from The Center for AIDS - Treatment of HIV Infection With Prednisolone (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO - Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Scientists Find HIV-Blocking Protein in Monkeys (February 25, 2004)
[Archived Article]
TRIM5-alpha is the first host protein found that specifically targets HIV's capsid.
From U.S. National Institute of Allergy and Infectious Diseases - Capsid Protein Assembly Inhibitors: Potential New Class of Antiviral Drugs (May 7, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Discovery Lays Groundwork for Potential New Class of Anti-HIV Drugs (March 31, 2003)
[Archived Article]
From U.S. National Institute of Allergy and Infectious Diseases - Digging Deeper at the Resistance Workshop (August 14, 2002)
[Archived Article]
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society - Zinc Finger Inhibitors (June 1, 2002)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - New Cancer Drugs Might Help Treat HIV -- But Research Not Done (April 12, 2002)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News - New Immune-Based Treatment Approach: Trial Recruiting in San Francisco (February 23, 2001)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.